´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-09±³À°ÀÏÀÚ : 2019-02-09
±³À°Àå¼Ò : ¼¿ï, ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ(¿ë»ê±¸ ÀÓÁ¤·Î 26 ¼ÒÀç)
±³À°ÁÖÁ¦ :
Á¦13ȸ Nephrology Board Review Course 2019ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : »ç¹«±¹ ¿¬¶ôó
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ :
ksn@ksn.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 09:10~09:40 Metabolic acidosis of CKD: pathogenesis, consequences, and treatment Áֱǿí(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 09:40~10:10 Hypokalemia: clinical perspectives on endocrine connections ±è¼ö¿Ï(Àü³²ÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 10:10~10:40 Dysnatremia in patients with neurologic disorders ±è¼¼Áß(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 10:50~11:15 Pathology and mechanisms of glomerular diseases ÀÓ¹üÁø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 11:15~11:40 Nephrotic syndrome (focusing on MCD and FSGS) ±èÈ¿»ó(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 11:40~12:05 Membranous nephropathy (idiopathic and secondary) ¿ÀÁöÀº(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:05~13:30 Membranoproliferative glomerulonephritis and C3 glomerulopathy ¿À¼¼¿ø(°í·ÁÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:30~13:55 Treatment of IgA nephropathy based on pathologic classification ÀÌÇÏÁ¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:55~14:20 Paraprotein-related kidney disease ÀÌÁ¤Àº(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 14:30~14:55 Effect of low salt and protein diet in CKD progression À̼º¿ì(À»ÁöÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 14:55~15:20 Optimal therapeutic strategies for CKD-MBD Á¤Áö¿ë(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 15:20~15:45 Diabetic kidney disease (current and future strategies) ÇѽÂÇõ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 15:45~16:10 Hyperuricemia in CKD ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 16:10~16:35 Medical management of obesity in CKD ±Ç¼ø±æ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 16:35~17:00 Update on renovascular disease ±èÅÂÈñ(ÀÎÁ¦ÀÇ´ë)